Quick Answer
CNS Pharmaceuticals, Inc. reported Earnings Per Share Diluted of $35.75 (loss) per share for the year ending 2025.
- CNS Pharmaceuticals, Inc. showed an increase of +92.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from CNS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.15 (loss) per share | Q3 2021: $0.14 (loss) per share | Q1 2022: $2.44 (loss) per share | Q2 2022: $2.67 (loss) per share | Q3 2022: $2.56 (loss) per share | Q1 2023: $2.59 (loss) per share | Q2 2023: $51.86 (loss) per share | Q3 2023: $54.14 (loss) per share | Q1 2024: $1,020.48 (loss) per share | Q2 2024: $4,049.20 (loss) per share | Q3 2024: $153.20 (loss) per share | Q1 2025: $1.58 (loss) per share | Q2 2025: $6.42 (loss) per share | Q3 2025: $5.76 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), CNS Pharmaceuticals, Inc.'s Earnings Per Share Diluted has declined by 116.7%.
- Historical annual values: Fiscal year 2025: $35.75 (loss) per share | Fiscal year 2024: $466.89 (loss) per share | Fiscal year 2023: $12,509.11 (loss) per share | Fiscal year 2022: $11.22 (loss) per share | Fiscal year 2021: $16.50 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: